Insect Cell Lines Market Trends

  • Report ID: 5339
  • Published Date: Jan 03, 2025
  • Report Format: PDF, PPT

Insect Cell Lines Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Public Interest in Genetically Modified Organisms– The genetic modification of insects has emerged as a significant topic of study as genetically modified organisms, or GMOs, are organisms that have had their genomes altered via the use of recombinant DNA technology.
  • Growing Popularity of Cell-Based Therapies- Cell and gene therapies hold the potential to provide patients with life-altering medications therefore, the use of cell-based therapeutics is expanding quickly, and insect cell lines are being utilized to manufacture these therapies as they can be used as cutting-edge models with special benefits like higher efficiency and lower cost.
  • Spiking Prevalence of Chronic Diseases- Insect cell lines are extensively used in the pharmaceutical sector as they aid in producing drugs and vaccines for the treatment of several chronic conditions. According to the World Health Organization (WHO), Noncommunicable diseases (NCDs) account for 41 million annual fatalities, or around 74% of all fatalities worldwide.
  • Surge in Drug Development- In the early stages of drug screening, insect cell expression is common, as they provide several industrial benefits over mammalian cells, including less need for CO2, lower energy needs, and fewer biosafety requirements.
  • Increasing Usage in Toxicity Screening- Insect cell cultures are used to compare the toxicities of various substances in both target organisms and non-target organisms as they are capable of mimicking certain aspects of mammalian cell responses.
  • Rising Trend of Personalized Medicine- Insect cell lines are used in the production of viral vectors that have been developed to offer personalized medications that can be used for a variety of applications in medical biotechnology and biological sciences.
  • Expanding Usage in Virus Research- Insect-derived cell lines offer useful resources for the controlled research of insect viruses that are spread between insects and plants.

Challenges

  • High Cost of Insect Cell Lines – The cost of maintaining controlled environments is usually high as insect cell lines must be kept at 37°C and are grown at 27°C for optimum growth in a carbon dioxide-rich environment. Besides this, eliminating microbial contamination is a difficult but necessary first step in the development of an insect cell line to clean insect tissues, whereby researchers employ a variety of techniques that consume a lot of time, energy, and money.
  • Competition Arising from the Presence of Other Cell-Based Technologies
  • Limited Funding can Impede the Overall Efficiency of Insect Cell Lines

Base Year

2024

Forecast Year

2025-2037

CAGR

11.5%

Base Year Market Size (2024)

USD 1.12 billion

Forecast Year Market Size (2037)

USD 4.61 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of insect cell lines is evaluated at USD 1.23 billion.

The insect cell lines market size was over USD 1.12 billion in 2024 and is poised to exceed USD 4.61 billion by 2037, witnessing over 11.5% CAGR during the forecast period i.e., between 2025-2037. Increasing production of vaccines and the rising need for insect-derived products will drive the market growth.

North America industry is expected to account for largest revenue share of 35% by 2037, impelled by increasing spending on the production of vaccines in the region.

The major players in the market are Sigma-Aldrich Corporation, GE Healthcare Technologies Inc., Lonza Group, Becton, Dickinson & Company, HiMedia Laboratories LLC, Takara Bio Inc., CellGenix GmbH, Atlanta Biologicals Inc., PromoCell GmbH.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos